You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • FRI0227 Sarilumab significantly suppresses circulating biomarkers of bone resorption and cardiovascular risk compared with adalimumab: biomarker analysis from the phase 3 monarch study

Article metrics

Article menu

Download PDFPDF

Poster Presentations
Rheumatoid arthritis - other biologic treatment
FRI0227 Sarilumab significantly suppresses circulating biomarkers of bone resorption and cardiovascular risk compared with adalimumab: biomarker analysis from the phase 3 monarch study
Free

 

Online download statistics by month:

Online download statistics by month: June 2017 to March 2024

AbstractFullPdf
Jun 2017601
Jul 20172801
Aug 20172201
Sep 20172602
Oct 20171402
Nov 20174406
Dec 20171602
Jan 20183405
Feb 20182804
Mar 20181601
Apr 20183402
May 20182001
Jun 20181800
Jul 20181807
Aug 20181402
Sep 20181807
Oct 2018808
Nov 201826016
Dec 20181802
Jan 2019603
Feb 2019602
Mar 20191405
Apr 201918010
May 2019608
Jun 20191407
Jul 20191806
Aug 20191204
Sep 2019201
Oct 2019802
Nov 20191204
Dec 2019803
Jan 20202806
Feb 20201005
Mar 2020601
Apr 2020802
May 20201204
Jun 2020602
Jul 20201003
Aug 2020607
Sep 20201802
Oct 2020602
Nov 20201004
Dec 2020802
Jan 2021602
Feb 2021604
Mar 2021401
Apr 2021202
May 2021001
Jul 2021006
Aug 20211014
Sep 20211017
Oct 202113024
Nov 20217018
Dec 20211002
Jan 2022201
Feb 20221501
Mar 2022204
Apr 2022700
May 2022607
Jun 20221003
Jul 2022800
Aug 20223803
Sep 20221006
Oct 2022603
Nov 20221001
Dec 2022600
Jan 20231701
Feb 2023800
Mar 20231400
Apr 2023403
May 2023804
Jun 2023601
Jul 2023405
Aug 2023201
Sep 20231100
Oct 2023600
Nov 2023401
Dec 20231203
Jan 2024202
Feb 2024400
Mar 202419023
Total9510329